Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 6/2006

01-12-2006 | CASE REPORT

Quinupristin/dalfopristin and voriconazole controlled Staphylococcus epidermidis pneumonia and chronic necrotizing aspergillosis in a patient with severe lung degradation consequent to multiple treatments for Hodgkin's lymphoma

Authors: Hideharu Muto, Shin Kaneko, Takayuki Machino, Yasushi Okoshi, Harumi Y. Mukai, Kazumi Suzukawa, Yuichi Hasegawa, Shigehiko Imagawa, Hiroshi Kojima, Yukio Ishii, Shigemi Hitomi, Toshiro Nagasawa

Published in: Journal of Infection and Chemotherapy | Issue 6/2006

Login to get access
Metadata
Title
Quinupristin/dalfopristin and voriconazole controlled Staphylococcus epidermidis pneumonia and chronic necrotizing aspergillosis in a patient with severe lung degradation consequent to multiple treatments for Hodgkin's lymphoma
Authors
Hideharu Muto
Shin Kaneko
Takayuki Machino
Yasushi Okoshi
Harumi Y. Mukai
Kazumi Suzukawa
Yuichi Hasegawa
Shigehiko Imagawa
Hiroshi Kojima
Yukio Ishii
Shigemi Hitomi
Toshiro Nagasawa
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Journal of Infection and Chemotherapy / Issue 6/2006
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-006-0495-2

Other articles of this Issue 6/2006

Journal of Infection and Chemotherapy 6/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine